MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

Omnicell Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

50.25 5.97

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

47.22

Max

50.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-177K

5.5M

Pardavimai

20M

311M

P/E

Sektoriaus vid.

109.14

87.826

Pelnas, tenkantis vienai akcijai

0.51

Pelno marža

1.758

Darbuotojai

3,600

EBITDA

524K

31M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+14.23% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

753M

2.2B

Ankstesnė atidarymo kaina

44.28

Ankstesnė uždarymo kaina

50.25

Naujienos nuotaikos

By Acuity

22%

78%

52 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Omnicell Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-07 23:11; UTC

Uždarbis

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026-01-07 22:55; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026-01-07 21:39; UTC

Pagrindinės rinkos jėgos

Raytheon Down Following Trump Post Criticizing Company

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026-01-07 20:03; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026-01-07 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-07 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026-01-07 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026-01-07 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026-01-07 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026-01-07 22:48; UTC

Rinkos pokalbiai

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026-01-07 22:46; UTC

Uždarbis

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026-01-07 22:45; UTC

Uždarbis

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 22:42; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026-01-07 22:40; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026-01-07 22:31; UTC

Rinkos pokalbiai

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026-01-07 22:22; UTC

Rinkos pokalbiai

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026-01-07 22:01; UTC

Rinkos pokalbiai

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026-01-07 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-07 21:46; UTC

Rinkos pokalbiai

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026-01-07 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026-01-07 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026-01-07 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 20:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026-01-07 19:58; UTC

Rinkos pokalbiai

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026-01-07 19:48; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Akcijų palyginimas

Kainos pokytis

Omnicell Inc Prognozė

Kainos tikslas

By TipRanks

14.23% į viršų

12 mėnesių prognozė

Vidutinis 54.2 USD  14.23%

Aukščiausias 63 USD

Žemiausias 46 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Omnicell Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

5

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

24.23 / 30.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

52 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat